Antimicrobial PK in Infants With Suspected or Confirmed Infection

Overview

The purpose of this protocol is to provide a mechanism for the ongoing collection of blood and urine samples in newborns that will be used to measure levels of antimicrobial products used in the newborn population where there are limited pharmacokinetic data in either premature or term infants.

Full Title of Study: “Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns – add-on Study)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: October 2010

Detailed Description

Greater than 90% of infants born <32 weeks admitted to critical care nurseries are treated with antimicrobial agents during their NICU hospitalization. Most antimicrobial products used in the neonatal population lack some aspect of pharmacokinetic information specific to neonates. Dosing is based largely on pharmacokinetic data from older children or in some cases, adults. This study will also establish a bank of urine samples from newborns treated with antimicrobial and/or antifungal therapy and to characterize the urinary proteome in selected samples. The sites of the NIH-sponsored Pediatric Pharmacology Research Network (PPRU) have access to appropriate assays using microliter amounts of serum and a large pool of potential subjects to generate meaningful data that will 1. Guide dosing of commonly used antimicrobial agents, and 2. Provide preliminary data for future industry and government trials in the nursery.

Interventions

  • Drug: Ampicillin
    • Drug prescribed per routine medical care.
  • Drug: Metronidazole
    • Drug prescribed per routine medical care.
  • Drug: Piperacillin/Tazobactam
    • Drug prescribed per routine medical care.
  • Drug: Acyclovir
    • Drug prescribed per routine medical care.
  • Drug: Amphotericin B
    • Drug prescribed per routine medical care.
  • Drug: Ambisome
    • Drug prescribed per routine medical care.
  • Drug: Anidulafungin
    • Drug prescribed per routine medical care.
  • Drug: Caspofungin
    • Drug prescribed per routine medical care.

Arms, Groups and Cohorts

  • <26 weeks
    • Subjects <26 weeks gestational age
  • 26-29 weeks
    • Subjects 26-29 weeks gestational age
  • 30-32 weeks
    • Subjects 30-32 weeks gestational age

Participating in This Clinical Trial

Inclusion Criteria

  • Infants ≤32 weeks and 6 days EGA with high probability of receiving one of the antimicrobial agents listed are eligible for study. – Age younger than 120 days – Written informed consent from parent or legal guardian – Infants likely to survive beyond 48 hours after enrollment Exclusion Criteria:

  • Failure to consent

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 120 Days

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Duke University
  • Collaborator
    • Pediatric Pharmacology Research Units Network
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Danny Benjamin, MD, Principal Investigator, PPRU
    • Mary Jayne Kennedy, Pharm, D, Principal Investigator, Louisville-PPRU

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.